EIF2A and cholangiocarcinoma: First, experiments in cholangiocarcinoma (CCA) have proven that the suppression of nc886 provokes the canonical PKR/eIF2α cell death pathway in non-malignant cholangiocyte cells, but not in CCA cells [12].